After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is the most formidable challenge to …

Background More than 1· 8 million new cases of HIV-1 infection were diagnosed worldwide
in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been …

Background HIV and herpes simplex virus type 2 (HSV-2) infections cause a substantial
global disease burden and are epidemiologically correlated. Two previous systematic …

In the last century, vaccination has been the most effective medical intervention to reduce
death and morbidity caused by infectious diseases. It is believed that vaccines save at least …

Background Adenovirus-vectored (Ad-vectored) vaccines are typically administered via im
injection to humans and are incapable of inducing respiratory mucosal immunity. However …

Background A safe and effective vaccine for the prevention of human immunodeficiency
virus type 1 (HIV-1) infection is a global priority. We tested the efficacy of a DNA prime …

This year marks the thirtieth anniversary of the publication of the study that first reported the
isolation of HIV-1. In this Timeline article, we provide a historical perspective of some of the …

Introduction The development of an effective vaccine to protect against HIV is a longstanding
global health need complicated by challenges inherent to HIV biology and to the execution …

Executive summary After more than a decade of major achievements, the AIDS response is
at a crucial juncture, both in terms of its immediate trajectory and its sustainability, as well as …